ADAR1 Capital Management, LLC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-21 4:15 pm Sale | 2025-08-21 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,389,264 13.270% | -1,700 (-0.03%) | Filing |
| 2025-05-12 11:29 am Unchanged | 2025-05-12 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.270% | 0 (Unchanged) | Filing |
| 2025-05-08 4:39 pm Unchanged | 2025-05-08 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.270% | 0 (Unchanged) | Filing |
| 2025-04-28 6:43 pm Unchanged | 2025-04-24 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.290% | 0 (Unchanged) | Filing |
| 2025-04-11 8:32 pm Purchase | 2025-04-04 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.290% | 5,390,964 (New Position) | Filing |